Longitudinal ctDNA profiling reveals genomic risk and molecular response to bireociclib in advanced breast cancer
This study shows that tracking tumor DNA in blood can help predict outcomes, monitor treatment response, and reveal resistance in women receiving bireociclib plus fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer.